At the center of the country, Colorado accelerates the full spectrum of health innovation. Promising startups translate discoveries into companies. Growth-stage organizations advance clinical programs and prepare for market. Longtime anchor companies invest in research, manufac turing, workforce development, and the partnerships emerging companies need to scale. For Elyse Blazevich, Colorado’s location and culture offer advantages. “Colorado’s geography shapes how we build,” says Blazevich, President & CEO of Colorado BioScience Association and President of Colorado BioScience Institute. “We offer ease of access to both coasts but remain grounded here. Leaders stay accessible and focused on the science. That discipline helps com panies make thoughtful decisions and use capital effectively.” Global companies with deep roots in the state serve as anchors, attracting and growing talent and providing leadership in a mature ecosystem. Medtronic has operated in Colorado for more than five decades. Agilent Technologies is expanding its capacity to manufacture therapeutic oligonucleotides. Terumo Blood and Cell Technologies, headquar tered in Colorado, advances technologies used in blood and cell-based therapies. These companies deepen the state’s talent and regulatory expertise. They support supplier networks and create pathways for experienced leaders to guide new ventures. Five R-1 research universities generate discoveries and talent. Specialized infra structure gives companies room to grow. Investors, service providers, and economic development partners help move innova tions from concept to commercialization. Colorado’s workforce and scientific depth add to the opportunity. The state ranks second nationally for its percentage of bachelor’s degree holders and boasts a critical mass of cell and gene therapy companies. Investors find experienced talent, proven operators, and a growing pipeline of breakthroughs. CBSA’s Drive to Five: Colorado Life Sciences Innovation Tour brought that landscape into view. Investors, community leaders, economic developers, and site selectors stepped inside saw organiza tions from concept to commercialization thriving in the same ecosystem. “Researchers and founders work within reach of experienced operators, anchor companies, and leading research univer sities,” Blazevich says. “That proximity creates stronger companies and a more disciplined environment for investment.” Centered geographically and grounded in its approach, Colorado gives compa nies room to start, scale, and stay. The ecosystem combines emerging potential with established strength, creating value and advancing breakthroughs for patients. Colorado’s Ecosystem Demonstrates Strength at Every Stage Blazevich gathers input from a packed house of ecosystem leaders to inform future life sciences growth in Colorado. “ Colorado’s geography shapes how we build. ELYSE BLAZEVICH PRESIDENT & CEO COLORADO BIOSCIENCE ASSOCIATION PRESIDENT COLORADO BIOSCIENCE INSTITUTE 10 2026-27 BIOSCIENCE COLORADO
View this content as a flipbook by clicking here.